Feasibility of targeted next-generation sequencing of the TP53 and ATM genes in chronic lymphocytic leukemia

Leukemia

Volumn 28, Issue 3, 2014, Pages 694-696

  Mansouri, L ^a   Sutton, L A ^a   Ljungstrom V ^a   Sorqvist E F ^a   Gunnarsson, R ^b   Smedby, K E ^c   Juliusson, G ^b   Stamatopoulos, K ^a,d,e   Nilsson, M ^a,f   Rosenquist, R ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d INFORMATION TECHNOLOGIES INSTITUTE   (Greece)

^e G PAPANICOLAOU HOSPITAL   (Greece)

^f STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

ATM GENE; CHRONIC LYMPHATIC LEUKEMIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; GENE SEQUENCE; HUMAN; LETTER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TP53 GENE;

ATAXIA TELANGIECTASIA MUTATED PROTEINS; FEASIBILITY STUDIES; GENES, P53; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

EID: 84895830393     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.322     Document Type: Letter

References (16)

1. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
2. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
3. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37-50.
4. Gunnarsson R, Isaksson A, Mansouri M, Goransson H, Jansson M, Cahill N et al. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: A high-resolution genomic screening of newly diagnosed patients. Leukemia 2010; 24: 211-215.
5. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174.
6. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714-726.
7. Zenz T, Vollmer D, Trbusek M, Smardova J, Benner A, Soussi T et al. TP53 mutation profile in chronic lymphocytic leukemia: Evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia 2010; 24: 2072-2079.
8. Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012; 26: 1458-1461.
9. Skowronska A, Parker A, Ahmed G, Oldreive C, Davis Z, Richards S et al. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. J Clin Oncol 2012; 30: 4524-4532.
10. Johansson H, Isaksson M, Sorqvist EF, Roos F, Stenberg J, Sjoblom T et al. Targeted resequencing of candidate genes using selector probes. Nucleic Acids Res 2011; 39: E8.
11. de Miranda NF, Peng R, Georgiou K, Wu C, Sorqvist EF, Berglund M et al. DNA repair genes are selectively mutated in diffuse large B cell lymphomas. J Exp Med 2013; 210: 1729-1742.
12. Navrkalova V, Sebejova L, Zemanova J, Kminkova J, Kubesova B, Malcikova J et al. ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: Application of functional test using doxorubicin. Haematologica 2013; 98: 1124-1131.
13. Trbusek M, Malcikova J. TP53 aberrations in chronic lymphocytic leukemia. Adv Exp Med Biol 2013; 792: 109-131.
14. Mansouri L, Cahill N, Gunnarsson R, Smedby KE, Tjonnfjord E, Hjalgrim H et al. NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia. Leukemia 2013; 27: 512-514.
15. Quesada V, Ramsay AJ, Rodriguez D, Puente XS, Campo E, Lopez-Otin C. The genomic landscape of chronic lymphocytic leukemia: Clinical implications. BMC Med 2013; 11: 124.
16. Strefford JC, Sutton LA, Baliakas P, Agathangelidis A, Malcikova J, Plevova K et al. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: The case of SF3B1 and subset #2. Leukemia 2013; 27: 2196-2199..